HF
CRSP icon

HRT Financial’s CRISPR Therapeutics CRSP Stock Holding History

HRT Financial’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$430K Buy
+7,900
New +$416K ﹤0.01% 2806

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HRT Financial's CRSP Position: Q2 2026 in Review

HRT Financial increased its CRISPR Therapeutics (CRSP) stake by 91% in Q2 2026, buying an estimated $3.38M and bringing the position to 134,664 shares worth $7.34M. The position accounts for 0.01% of the portfolio, ranked #932.

HRT Financial first reported a position in CRSP in Q4 2018 and has held it in 13 quarters since. The position peaked at $16.5M in Q2 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • HRT Financial held 134,664 shares of CRISPR Therapeutics worth $7.34M as of Q2 2026.
  • HRT Financial bought 64,132 CRISPR Therapeutics shares in Q2 2026, an estimated $3.38M.
  • CRISPR Therapeutics made up 0.01% of HRT Financial's portfolio in Q2 2026, its #932 holding.
  • HRT Financial first reported a position in CRISPR Therapeutics in Q4 2018 and has held it in 13 quarters since.
  • HRT Financial's CRISPR Therapeutics position peaked at $16.5M in Q2 2021.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.